Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Harvoni and Ribavirin for HCV-Induced Insulin Resistance
NCT02760355Completed
- Start
- Mar 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ledipasvir in hepatitis C (HCV). Primary endpoint: Hepatitis C virus-induced insulin resistance at 6 weeks. Started Mar 2016; status: completed.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02760355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760355.